Notably, the combination of ML141 and anti‐PD‐1 antibody significantly reduced tumor growth (TGI = 86%) and prolonged survival time compared to the anti‐PD‐1 antibody alone group (Figure 6a,b). The gene discussed is PDCD1; the disease is neoplasm.